Chronic Lymphocytic Leukemia (CLL) Latest Advances
Find the Latest Research About Chronic Lymphocytic Leukemia (CLL)
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24982 publications
Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.
Journal: Leukemia & lymphoma
Published: April 11, 2026
Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eμ-TCL1 mice.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
CLO26-110: Novel Targeted Therapies for Central Nervous System Involvement in Chronic Lymphocytic Leukemia: A Systematic Review.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
Risk of Skin Cancer Among Patients With Chronic Lymphocytic Leukemia.
Journal: JAMA dermatology
Published: April 01, 2026
Bilateral Serous Maculopathy Associated with Acalabrutinib Therapy in Chronic Lymphocytic Leukemia.
Journal: Retinal cases & brief reports
Published: April 01, 2026
The APLC expert consensus recommendations on the management of chronic lymphocytic leukaemia in Asia.
Journal: Annals of the Academy of Medicine, Singapore
Published: April 01, 2026
Comprehensive phenotypic and clonality analysis of intraepithelial lymphocytes of intestinal T-cell lymphoma and chronic enteropathy in dogs.
Journal: Veterinary pathology
Published: March 31, 2026
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Journal: Pharmacological research
Published: March 31, 2026
HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
CRE26-049: Intrathecal Rituximab for Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Case Report and Literature Review.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Last Updated: 04/28/2026